Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new

Results from the VERTIS-CV trial show that SGLT-2 inhibitor Steglatro benefits heart and kidney health; hear expert opinions on SGLT-2 and GLP-1 medications Continue Reading »

The first study of people with diabetes and COVID-19 reveals troubling statistics and risk factors Continue Reading »

In exciting news, Tandem announced expanded clearance for the hybrid closed loop Control-IQ. The system is now available for children ages 6-13 Continue Reading »

Check out the third day highlights from ADA’s virtual 80th Scientific Sessions – including new insights on off label use in type 1 diabetes, type 2 diabetes remission, DIY closed loop, DSMES, and more! Continue Reading »

We bring you the most exciting news from day one, including updates on automated insulin delivery, ways that technology can reduce hypoglycemia, and new physical activity recommendations Continue Reading »

Early trial results found that SGLT-2 inhibitor Farxiga is highly effective for preventing and treating kidney disease in people with or without type 2 diabetes Continue Reading »

JDRF's Mission Summit in La Jolla, California highlighted JDRF's efforts into multiple cures, plus more on complications Continue Reading »

Trulicity can now be prescribed to reduce the risk of stroke and heart attack in adults with type 2 diabetes and with heart disease or those who at risk for heart disease Continue Reading »

Pages